Skip to main content

Advertisement

Articles

Page 1 of 25

  1. Long noncoding RNAs (lncRNAs) are known to regulate tumorigenesis and cancer progression, but their contributions to non-small-cell lung cancer (NSCLC) metastasis remain poorly understood. Our previous and oth...

    Authors: Zhenyao Chen, Xin Chen, Binbin Lu, Yu Gu, Qinnan Chen, Tianyao Lei, Fengqi Nie, Jingyao Gu, Jiali Huang, Chenchen Wei, Ming Sun and Zhaoxia Wang

    Citation: Journal of Hematology & Oncology 2020 13:7

    Content type: Research

    Published on:

  2. BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases. This phase I study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, ...

    Authors: Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu and Yuankai Shi

    Citation: Journal of Hematology & Oncology 2020 13:6

    Content type: Rapid communication

    Published on:

  3. Long non-coding RNAs (lncRNAs) possess significant regulatory functions in multiple biological and pathological processes, especially in cancer. Dysregulated lncRNAs in hepatocellular carcinoma (HCC) and their...

    Authors: Xueliang Zuo, Zhiqiang Chen, Wen Gao, Yao Zhang, Jinguo Wang, Junfeng Wang, Ming Cao, Juan Cai, Jindao Wu and Xuehao Wang

    Citation: Journal of Hematology & Oncology 2020 13:5

    Content type: Research

    Published on:

  5. The propensity of the activated neutrophils to form extracellular traps (NETs) is demonstrated in multiple inflammatory conditions. In this study, we investigated the roles of NETs in metastasis of hepatocellu...

    Authors: Lu-Yu Yang, Qin Luo, Lu Lu, Wen-Wei Zhu, Hao-Ting Sun, Ran Wei, Zhi-Fei Lin, Xiang-Yu Wang, Chao-Qun Wang, Ming Lu, Hu-Liang Jia, Jin-Hong Chen, Ju-Bo Zhang and Lun-Xiu Qin

    Citation: Journal of Hematology & Oncology 2020 13:3

    Content type: Research

    Published on:

  6. Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms...

    Authors: Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang…

    Citation: Journal of Hematology & Oncology 2020 13:2

    Content type: Research

    Published on:

  7. Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FD...

    Authors: Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro, Yanhua Wang, Olga Derman, Randin Nelson, Joan Uehlinger, Kira Gritsman, R. Alejandro Sica…

    Citation: Journal of Hematology & Oncology 2020 13:1

    Content type: Letter to the Editor

    Published on:

  8. In 2007, we initiated IMPACT, a precision medicine program for patients referred for participation in early-phase clinical trials. We assessed the correlation of factors, including genomically matched therapy,...

    Authors: Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu and Razelle Kurzrock

    Citation: Journal of Hematology & Oncology 2019 12:145

    Content type: Research

    Published on:

  9. Signaling pathways critical for embryonic development re-emerge in adult pancreas during tumorigenesis. Aspartate β-hydroxylase (ASPH) drives embryonic cell motility/invasion in pancreatic development/differen...

    Authors: Kosuke Ogawa, Qiushi Lin, Le Li, Xuewei Bai, Xuesong Chen, Hua Chen, Rui Kong, Yongwei Wang, Hong Zhu, Fuliang He, Qinggang Xu, Lianxin Liu, Min Li, Songhua Zhang, Katsuya Nagaoka, Rolf Carlson…

    Citation: Journal of Hematology & Oncology 2019 12:144

    Content type: Research

    Published on:

  10. The original article [1] contains several errors.

    Authors: Kai Zhao, Yuxin Zhou, Chen Qiao, Ting Ni, Zhiyu Li, Xiaotang Wang, Qinglong Guo, Na Lu and Libin Wei

    Citation: Journal of Hematology & Oncology 2019 12:143

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2015 8:41

  11. Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer therapy. The ability to reconstruct intra- and interpatient heterogeneity in cancer models is crucial for understandin...

    Authors: Han Fan, Utkan Demirci and Pu Chen

    Citation: Journal of Hematology & Oncology 2019 12:142

    Content type: Review

    Published on:

  12. Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malig...

    Authors: Lauren C. Fleischer, H. Trent Spencer and Sunil S. Raikar

    Citation: Journal of Hematology & Oncology 2019 12:141

    Content type: Review

    Published on:

  13. Statistical data on the incidence, mortality, and burden of breast cancer and the relevant risk factors are valuable for policy-making. We aimed to estimate breast cancer incidence, deaths, and disability-adju...

    Authors: Na Li, Yujiao Deng, Linghui Zhou, Tian Tian, Si Yang, Ying Wu, Yi Zheng, Zhen Zhai, Qian Hao, Dingli Song, Dai Zhang, Huafeng Kang and Zhijun Dai

    Citation: Journal of Hematology & Oncology 2019 12:140

    Content type: Research

    Published on:

  14. Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies that target hematological canc...

    Authors: Qinghua He, Xianhan Jiang, Xinke Zhou and Jinsheng Weng

    Citation: Journal of Hematology & Oncology 2019 12:139

    Content type: Review

    Published on:

  15. Endothelial-to-mesenchymal transition (EndoMT) can provide a source of cancer-associated fibroblasts which contribute to desmoplasia of many malignancies including pancreatic ductal adenocarcinoma (PDAC). We i...

    Authors: Chi-Shuan Fan, Li-Li Chen, Tsu-An Hsu, Chia-Chi Chen, Kee Voon Chua, Chung-Pin Li and Tze-Sing Huang

    Citation: Journal of Hematology & Oncology 2019 12:138

    Content type: Research

    Published on:

  18. METTL3 is an RNA methyltransferase that mediates m6A modification and is implicated in mRNA biogenesis, decay, and translation. However, the biomechanism through which METTL3 regulates MALAT1-miR-1914-3p-YAP axis...

    Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su

    Citation: Journal of Hematology & Oncology 2019 12:135

    Content type: Research

    Published on:

  21. Src, an oncoprotein that drives progression of head and neck squamous cell carcinoma (HNSCC), is commonly hyperactivated in this disease. Unfortunately, the clinical benefit of targeting Src is significantly d...

    Authors: Liwei Lang, Chloe Shay, Xiangdong Zhao, Yuanping Xiong, Xuli Wang and Yong Teng

    Citation: Journal of Hematology & Oncology 2019 12:132

    Content type: Research

    Published on:

  22. BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine ...

    Authors: Simona Soverini, Elisabetta Abruzzese, Monica Bocchia, Massimiliano Bonifacio, Sara Galimberti, Antonella Gozzini, Alessandra Iurlo, Luigiana Luciano, Patrizia Pregno, Gianantonio Rosti, Giuseppe Saglio, Fabio Stagno, Mario Tiribelli, Paolo Vigneri, Giovanni Barosi and Massimo Breccia

    Citation: Journal of Hematology & Oncology 2019 12:131

    Content type: Review

    Published on:

  23. Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation se...

    Authors: Hitendra Patel, Ryosuke Okamura, Paul Fanta, Charmi Patel, Richard B. Lanman, Victoria M. Raymond, Shumei Kato and Razelle Kurzrock

    Citation: Journal of Hematology & Oncology 2019 12:130

    Content type: Short report

    Published on:

  24. Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have been reported to date, some of them suc...

    Authors: Yuan Fang, Guochao Liao and Bin Yu

    Citation: Journal of Hematology & Oncology 2019 12:129

    Content type: Review

    Published on:

  26. Asparagine-linked (N-linked) glycosylation is ubiquitous and can stabilize immune inhibitory PD-1 protein. Reducing N-linked glycosylation of PD-1 may decrease PD-1 expression and relieve its inhibitory effects o...

    Authors: Xiaojuan Shi, Daiqun Zhang, Feng Li, Zhen Zhang, Shumin Wang, Yujing Xuan, Yu Ping and Yi Zhang

    Citation: Journal of Hematology & Oncology 2019 12:127

    Content type: Letter to the Editor

    Published on:

  27. Immunotherapy has become an emerging strategy for the treatment of cancer. Immunotherapeutic drugs have been increasing for clinical treatment. Despite significant advances in immunotherapy, the clinical appli...

    Authors: Zhongwei Zhao, Liyun Zheng, Weiqian Chen, Wei Weng, Jingjing Song and Jiansong Ji

    Citation: Journal of Hematology & Oncology 2019 12:126

    Content type: Review

    Published on:

  28. Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent developments in cancer immunotherapy have had significant clinical impact, only a subset of patients exhibits clinic...

    Authors: Li Yang, Aitian Li, Qingyang Lei and Yi Zhang

    Citation: Journal of Hematology & Oncology 2019 12:125

    Content type: Review

    Published on:

  29. Human pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint inhibitor (ICPi). While the mechanism is not completely clear, it has been recognized that tumor microenvironment (TME) plays ...

    Authors: Yu Pan, Fengchun Lu, Qinglin Fei, Xingxing Yu, Ping Xiong, Xunbin Yu, Yuan Dang, Zelin Hou, Wenji Lin, Xianchao Lin, Zheyang Zhang, Minggui Pan and Heguang Huang

    Citation: Journal of Hematology & Oncology 2019 12:124

    Content type: Research

    Published on:

  30. Mitosis is the process whereby an eukaryotic cell divides into two identical copies. Different multiprotein complexes are involved in the fine regulation of cell division, including the mitotic promoting facto...

    Authors: Andrea Ghelli Luserna di Rorà, Giovanni Martinelli and Giorgia Simonetti

    Citation: Journal of Hematology & Oncology 2019 12:123

    Content type: Review

    Published on:

  31. In the original article [1], the terms ‘osISET’ and ‘ISET’ within the ‘CTC capture’ sub-section of the Materials and Methods section have both been replaced with ‘CTCBIOPSY®’.

    Authors: Xiaobin Lin, Shuyi Wang, Min Sun, Chunxiao Zhang, Chen Wei, Chaogang Yang, Rongzhang Dou, Qing Liu and Bin Xiong

    Citation: Journal of Hematology & Oncology 2019 12:122

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:20

  32. N6-methyladenosine (m6A) methylation, one of the most common RNA modifications, has been reported to execute important functions that affect normal life activities and diseases. Most studies have suggested tha...

    Authors: Shuai Ma, Chen Chen, Xiang Ji, Jinbo Liu, Quanbo Zhou, Guixian Wang, Weitang Yuan, Quancheng Kan and Zhenqiang Sun

    Citation: Journal of Hematology & Oncology 2019 12:121

    Content type: Review

    Published on:

  33. The Editor-in-Chief would like to alert readers that the ownership of some of the data presented in this article [1]

    Authors: Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, Carlo Lucchesi, Scott R. Daigle, Elodie Richard, Audrey Laroche-Clary, François Le Loarer and Antoine Italiano

    Citation: Journal of Hematology & Oncology 2019 12:116

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:11

  34. Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and m...

    Authors: Chao Wu, Lina Zhang, Qierra R. Brockman, Fenghuang Zhan and Lijuan Chen

    Citation: Journal of Hematology & Oncology 2019 12:120

    Content type: Review

    Published on:

  35. Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2, and/or BCL6 oncogenes. Due to the simultaneous overexpression of thes...

    Authors: Yuanhui Liu, Nancy G. Azizian, Yaling Dou, Lan V. Pham and Yulin Li

    Citation: Journal of Hematology & Oncology 2019 12:119

    Content type: Rapid communication

    Published on:

  37. The original article [1] contains an error in authorship whereby author, Robert Weinkove’s name is mistakenly inverted. The configuration noted in this Correction article should be considered instead along wit...

    Authors: Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang…

    Citation: Journal of Hematology & Oncology 2019 12:117

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2018 11:25

  39. Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We...

    Authors: Alice Ramassone, Andrea D’Argenio, Angelo Veronese, Alessio Basti, Shimaa Hassan AbdelAziz Soliman, Stefano Volinia, Cristian Bassi, Sara Pagotto, Manuela Ferracin, Laura Lupini, Elena Saccenti, Veronica Balatti, Felice Pepe, Laura Z. Rassenti, Idanna Innocenti, Francesco Autore…

    Citation: Journal of Hematology & Oncology 2019 12:114

    Content type: Letter to the Editor

    Published on:

  41. Increased liver stiffness exerts a detrimental role in driving hepatocellular carcinoma (HCC) malignancy and progression, and indicates a high risk of unfavorable outcomes. However, it remains largely unknown ...

    Authors: Yinying Dong, Qiongdan Zheng, Zhiming Wang, Xiahui Lin, Yang You, Sifan Wu, Yaohui Wang, Chao Hu, Xiaoying Xie, Jie Chen, Dongmei Gao, Yan Zhao, Weizhong Wu, Yinkun Liu, Zhenggang Ren, Rongxin Chen…

    Citation: Journal of Hematology & Oncology 2019 12:112

    Content type: Research

    Published on:

  42. Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatm...

    Authors: E. Krasniqi, G. Barchiesi, L. Pizzuti, M. Mazzotta, A. Venuti, M. Maugeri-Saccà, G. Sanguineti, G. Massimiani, D. Sergi, S. Carpano, P. Marchetti, S. Tomao, T. Gamucci, R. De Maria, F. Tomao, C. Natoli…

    Citation: Journal of Hematology & Oncology 2019 12:111

    Content type: Review

    Published on:

  43. Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients need at least one systemic therapy at different phases of their treatment for HCC. S...

    Authors: Xiao-Dong Zhu and Hui-Chuan Sun

    Citation: Journal of Hematology & Oncology 2019 12:110

    Content type: Review

    Published on:

  44. The original article [1] contained an error in Fig. 7c whereby the same flow image was accidentally misused for the second and fourth group.

    Authors: Lufeng Zheng, Qianqian Guo, Chenxi Xiang, Shijia Liu, Yuzhang Jiang, Lanlan Gao, Haiwei Ni, Ting Wang, Qiong Zhao, Hai Liu, Yingying Xing, Yaohui Wang, Xiaoman Li and Tao Xi

    Citation: Journal of Hematology & Oncology 2019 12:109

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:23

  45. Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leuke...

    Authors: Jiří Pavlů, Myriam Labopin, Riitta Niittyvuopio, Gerard Socié, Ibrahim Yakoub-Agha, Depei Wu, Peter Remenyi, Jakob Passweg, Dietrich W. Beelen, Mahmoud Aljurf, Nicolaus Kröger, Hélène Labussière-Wallet, Zinaida Perić, Sebastian Giebel, Arnon Nagler and Mohamad Mohty

    Citation: Journal of Hematology & Oncology 2019 12:108

    Content type: Research

    Published on:

  46. Hodgkin lymphoma (HL) is an uncommon B cell lymphoma. We assessed the global, regional, and national burden of HL from 1990 to 2017, by gender, age, and social-demographic index (SDI).

    Authors: Linghui Zhou, Yujiao Deng, Na Li, Yi Zheng, Tian Tian, Zhen Zhai, Si Yang, Qian Hao, Ying Wu, Dingli Song, Dai Zhang, Jun Lyu and Zhijun Dai

    Citation: Journal of Hematology & Oncology 2019 12:107

    Content type: Research

    Published on:

  47. Cancer/testis antigens (CTAs) are a special type of tumor antigen and are believed to act as potential targets for cancer immunotherapy.

    Authors: Yuan Mao, Weifei Fan, Hao Hu, Louqian Zhang, Jerod Michel, Yaqin Wu, Jun Wang, Lizhou Jia, Xiaojun Tang, Li Xu, Yan Chen, Jin Zhu, Zhenqing Feng, Lin Xu, Rong Yin and Qi Tang

    Citation: Journal of Hematology & Oncology 2019 12:106

    Content type: Research

    Published on:

  49. Additional sex combs-like 1 (ASXL1) mutations have been described in all forms of myeloid neoplasms including chronic myelomonocytic leukemia (CMML) and associated with inferior outcomes, yet the molecular pathog...

    Authors: Rabindranath Bera, Ming-Chun Chiu, Ying-Jung Huang, Tung-Huei Lin, Ming-Chung Kuo and Lee-Yung Shih

    Citation: Journal of Hematology & Oncology 2019 12:104

    Content type: Research

    Published on:

  50. Circular RNAs (circRNAs) represent a type of endogenous noncoding RNAs that are generated by back-splicing events and favor repetitive sequences. Recent studies have reported that cancer-associated chromosomal...

    Authors: Wei Huang, Ke Fang, Tian-Qi Chen, Zhan-Cheng Zeng, Yu-Meng Sun, Cai Han, Lin-Yu Sun, Zhen-Hua Chen, Qian-Qian Yang, Qi Pan, Xue-Qun Luo, Wen-Tao Wang and Yue-Qin Chen

    Citation: Journal of Hematology & Oncology 2019 12:103

    Content type: Research

    Published on:

JHO logo
Submit manuscript

Follow

Annual Journal Metrics

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Advertisement

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us